Review of scientific literature highlights 450 studies assessing the therapeutic efficacy of cannabis and cannabinoids
The report covers 23 different patient groups, including autism, chronic pain, diabetes and post-traumatic stress disorder.
The National Organization for the Reform of Marijuana Laws (NORML) has updated its Clinical Applications For Cannabis & Cannabinoids report and the publication now highlights 450 peer-reviewed studies assessing the safety and efficacy of whole-plant cannabis and individual cannabinoids.
The update arrives four years since the last report and contains nearly 100 new studies, according to a blog post from NORML.
The report covers 23 different patient groups, including autism, chronic pain, diabetes and post-traumatic stress disorder, among other conditions.
Citing the National Library of Medicine, the world’s largest medical library, NORML highlights that 2020 was a banner year for cannabis research, with more than 3,500 scientific papers published on the subject. So far in 20201, an additional 2,600 papers have been published.
An introduction to the report, written by Paul Armentano, NORML’s deputy director, notes that the focus of cannabis research has also changed in recent years with scientists now exploring the potential role of cannabinoids to modulate disease.
Armentano points to research investigating cannabinoids’ capacity to moderate conditions like multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease, as well as research into neurological disorders such as Alzheimer’s disease.
Assessing the Therapeutic Efficacy of Cannabis & Cannabinoids